Quantcast

Latest XTL Biopharmaceuticals Ltd. Stories

2014-07-16 08:29:40

HERZLIYA, Israel, July 16, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that an overview of its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE) is included in an article titled, Novel Approaches to the Development of...

2014-06-12 08:29:12

Company Must Remedy Noncompliance with Audit Committee Requirements as Set Forth in Listing Rule 5605 HERZLIYA, Israel, June 12, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that it received a letter from the Nasdaq Stock Market LLC ("Nasdaq") dated...

2014-05-19 08:28:15

HERZLIYA, Israel, May 19, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of consultants Lee S. Simon, MD, FACP, FACR and David Isenberg, MD, for the planned Phase II trial for the Company's hCDR1 compound for the treatment of...

2014-04-02 16:31:44

HERZLIYA, Israel, April 2, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the year ended December 31, 2013. Company Highlights: -- Reorganized and strengthened management team -- Appointed Josh...

2014-03-25 08:29:48

HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1...

2014-01-08 08:28:37

HERZLIYA, Israel, January 8, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related